Provided By PR Newswire
Last update: Sep 24, 2025
MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment.
Read more at prnewswire.comNASDAQ:HOTH (10/27/2025, 12:54:52 PM)
1.38
+0.01 (+0.73%)
Find more stocks in the Stock Screener


